The underlying technology for SQZ Biotech was developed as part of Armon's PhD work at MIT. As a founder and CEO of the company, he hopes to deliver on our vision for the development of novel cell-based therapies capable of engineering a patient’s own immune system to combat diseases more effectively. We have made rapid progress over the years with our technology being recognized as one of the Top 10 World Changing Ideas by Scientific American, and the company making the list of top 15 Biotech Companies poised to change the world (published by Fierce Biotech). Our recent $500M deal with Roche, the largest oncology company in the world, further highlights our potential to address longstanding challenges in the field and develop novel treatments that are applicable to a broad range of diseases.

Background: Dr. Sharei received his B.S. with Honors and Distinction from Stanford University and my Ph.D. in Chemical Engineering from MIT, under the guidance of Profs. Klavs Jensen and Robert Langer, both renowned scientists. He was a national finalist for the NIH Director’s Early Independence Award in 2013 and was a Ragon Institute Fellow at Harvard Medical School. He is co-author of over 14 peer-reviewed publications and an inventor on over 10 patents. His main drive is the desire to make the world a better place by developing novel therapeutic modalities.